Imitrex – Mama En Linea http://mamaenlinea.com/ Sat, 02 Jul 2022 13:16:35 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://mamaenlinea.com/wp-content/uploads/2021/10/icon-120x120.png Imitrex – Mama En Linea http://mamaenlinea.com/ 32 32 2023: Check candidates’ files before voting, Fashola begs Nigerians https://mamaenlinea.com/2022/06/29/2023-check-candidates-files-before-voting-fashola-begs-nigerians/ Wed, 29 Jun 2022 11:13:30 +0000 https://mamaenlinea.com/2022/06/29/2023-check-candidates-files-before-voting-fashola-begs-nigerians/ Babatunde Fashola, the Minister of Works and Housing, has urged Nigerians to vote in the 2023 elections based on their track record. Mr Fashola made his comments on Tuesday at the sixth annual BRF GABFEST in Lagos. Mr Fashola had reacted to someone who noted that Nigerians might vote “angry” in the 2023 elections. He […]]]>

Babatunde Fashola, the Minister of Works and Housing, has urged Nigerians to vote in the 2023 elections based on their track record.

Mr Fashola made his comments on Tuesday at the sixth annual BRF GABFEST in Lagos.

Mr Fashola had reacted to someone who noted that Nigerians might vote “angry” in the 2023 elections. He urged voters to look into the backgrounds of candidates for government office in the upcoming elections.

“I urge you to vote by looking at what candidates have done before, it’s like asking for references during an interview or talking to a former employer. Here’s how to recruit an employee. Not out of anger,” Mr. Fashola.

-Advertising-

Although Mr Fashola tasked Nigerians with “political employers” to hold public debates and town halls, he told them not to expect all candidates to attend.

“In doing so, we have to be sensitive, because the candidates cannot attend all the debates and public meetings. In some cases, we must be prepared to accept their accredited spokesperson, but that must be the exception and not the rule,” Fashola said. “I urge you to vote by looking at what the candidates have done before.” , the former Lagos governor said.

]]>
Terrorist arrested with three explosive devices https://mamaenlinea.com/2022/06/28/terrorist-arrested-with-three-explosive-devices/ Tue, 28 Jun 2022 21:26:02 +0000 https://mamaenlinea.com/2022/06/28/terrorist-arrested-with-three-explosive-devices/ The Nigerian Security and Civil Defense Corps (NSCDC) in Cross River arrested a 31-year-old Aniebet John with suspected improvised explosive device, IEDs. NSCDC state commander Samuel Fadeyi, parading the suspect on Tuesday at the command headquarters in Calabar, said NSCDC officers arrested the suspect on June 25. Fadeyi confirmed that the suspect was arrested with […]]]>

The Nigerian Security and Civil Defense Corps (NSCDC) in Cross River arrested a 31-year-old Aniebet John with suspected improvised explosive device, IEDs.

NSCDC state commander Samuel Fadeyi, parading the suspect on Tuesday at the command headquarters in Calabar, said NSCDC officers arrested the suspect on June 25.

Fadeyi confirmed that the suspect was arrested with the three explosives including three connecting elements.

According to him, the suspect was arrested in the Akamkpa Local Government Area (LGA) of the state as he attempted to pass the explosives to an unidentified source in the Obubra LGA of the state.

-Advertising-

“The lady was trying to send the device which she had sealed in a nylon bag to Obubra LGA.

“Sending explosives on public transport is illegal, so of course we intercepted this lady who said someone sent her to send to another person.

“We are on the trail of the other suspects who are also involved but now at large,” he said.

The commander noted that upon investigation, they found out that the suspect’s husband is a master explosives worker who works at a construction company.

READ ALSO: Terrorists ban political activities in Kaduna

He explained that the suspect explosives were among those used in one of Akamkpa’s construction companies and that the husband could have smuggled.

He further said that the command would transfer the matter to the Department of State Services for further investigation.

“We have a unit called the Chemical, Biological, Radiological, Nuclear and Explosives Unit which acquaints us with some of the explosives in their packages.

“When an explosive moves, the national security adviser knows it.

“The National Security Advisor informs security agencies of the origin, route and destination so that we can keep track of them and ensure that they are used for this purpose.

“This explosive device is capable of causing more damage to humans and property if it detonates,” he said.

He urged residents of the state to be vigilant about their safety and to report any suspicious person or group of people around them to security agencies.

The suspect said her husband gave her the suspicious devices to hand over to someone from Obubra local government.

She explained that she had no other knowledge of the device other than the husband’s use of it at the time.

]]>
Why street begging is out of control in urban areas – PDP leader https://mamaenlinea.com/2022/06/23/why-street-begging-is-out-of-control-in-urban-areas-pdp-leader/ Thu, 23 Jun 2022 17:17:32 +0000 https://mamaenlinea.com/2022/06/23/why-street-begging-is-out-of-control-in-urban-areas-pdp-leader/ By Gideon Adonai With the upsurge of beggars and vagrants in urban towns in Nigeria, an opposition party leader has revealed the cause of the incessant begging and vagrancy behavior of some locals. Peoples Democratic Party (PDP) representative Umar Nuhu Gusau lamented that banditry activities in Zamfara state have forced villagers to abandon their communities […]]]>

By Gideon Adonai

With the upsurge of beggars and vagrants in urban towns in Nigeria, an opposition party leader has revealed the cause of the incessant begging and vagrancy behavior of some locals.

Peoples Democratic Party (PDP) representative Umar Nuhu Gusau lamented that banditry activities in Zamfara state have forced villagers to abandon their communities and migrate to urban areas to beg.

Gusau explained that most of the villagers had no business other than farming, saying that since the bandits took over almost every community in the states, they abandoned their communities and farmlands.

-Advertising-

Speaking in the state capital, the PDP leader argued that the terrorists have occupied their farmlands rendering them jobless as if they have no government in the state.

READ ALSO: Why are we evacuating beggars, street urchins and others to Akinyele Resettlement Centre? The government of Oyo

“There are thousands of widows whose husbands were killed by the rampaging bandits, resulting in the influx of villagers to urban areas for survival due to banditry activities.

He said agricultural activities are no longer thriving in the state because bandits have taken full control of the rural areas of the state and can unleash terrorist attacks whenever and wherever they want without any interruption.

He lamented that Governor Matawalle escalated the whole matter when he publicly stated that Almajeris rejected in other states should come to Zamfara, pointing out that the Governor had made no provision for their feeding and upkeep.

“When young orphans have no means of subsistence, they would be incited to join evil societies to make ends meet. We have heard of children under the age of 10 being caught up in banditry activities”

When asked to comment on the efforts of the federal and state governments to curb the long-dominated banditry activities in the state, Gusau said that if the governments were serious, the ugly situation would have been greatly reduced.

]]>
UN commits to supporting sustainable businesses in Nigeria https://mamaenlinea.com/2022/06/18/un-commits-to-supporting-sustainable-businesses-in-nigeria/ Sat, 18 Jun 2022 13:25:08 +0000 https://mamaenlinea.com/2022/06/18/un-commits-to-supporting-sustainable-businesses-in-nigeria/ The UN Global Compact Network in Nigeria has pledged to promote greater cross-functional collaboration among businesses to tackle issues related to sustainability in the post-COVID-19 era. UN Global Compact Network Nigeria is a UN Global Compact business-led sustainability initiative that was launched in Nigeria in 2007 at the Nigerian Economic Summit. Ms. Soromidayo George, Chairperson […]]]>

The UN Global Compact Network in Nigeria has pledged to promote greater cross-functional collaboration among businesses to tackle issues related to sustainability in the post-COVID-19 era.

UN Global Compact Network Nigeria is a UN Global Compact business-led sustainability initiative that was launched in Nigeria in 2007 at the Nigerian Economic Summit.

Ms. Soromidayo George, Chairperson of the UN Global Compact Network in Nigeria, said so on Friday during the Open Day and Onboarding Session of the UN Global Compact Network in Nigeria.

Ms. George was represented at the event by Ms. Uto Ukpanah, Board Member of UN Global Compact Network Nigeria and Corporate Secretary of MTN Nigeria Plc.

-Advertising-

According to her, the event was themed: “Business Case for Sustainability” aimed to encourage struggles against global uncertainty, economic recession, climate change and social development issues affecting the future of humanity.

READ ALSO: Sterling Bank Earnings Up 20% In 2021

She said: “The theme resonates with how we can promote greater cross-functional collaboration to address some of our nation’s greatest sustainability challenges.

“Our local network works tirelessly to drive local linkages and catalyze businesses and stakeholders to embrace our ten principles and set ambitious targets to achieve the 2030 Agenda in Nigeria.

“We strive to mobilize a local movement of sustainable businesses and actors with the aim of improving the lives of future generations; guided by the ten universal principles and the 17 SDGs,

[READ ALSO] 2023: We speak with Peter Obi – Kwankwaso provides update on LP/NNPP merger

“The UN Global Compact Network in Nigeria helps businesses and stakeholders understand what responsible business means in a global and local context and provides guidance to translate sustainability commitments into action.

“Corporate sustainability, as we know it today, encompasses ‘the long-term value of a business in financial, environmental, social and ethical or governance terms’.

The event was organized by the UN Global Compact Network Nigeria in collaboration with its office in New York.

The Ten Principles have been endorsed by more than 10,000 Global Compact signatories, many of the multinationals here today have their parent companies as members.

She commended the SDGs, the African Continental Free Trade Agreement, the 2022 Conference of Parties on Climate Change (COP 27) in Africa and the African Union’s Agenda 2063 for providing economic opportunities in Africa. , especially in Nigeria.

The chairman of the organization urged Nigerian businesses to consider human rights, labour, environment and anti-corruption and share critical ideas, in order to bridge the inequality gap in terms of of business sustainability in the country.

Also speaking, Naomi Nwokolo, Executive Director of the UN Global Compact Network in Nigeria and Chairperson of the African Regional Network Council – UN Global Compact, stressed the need for commitment to business principles to achieve the Goals.

She urged participants to remain committed to the implementation of the ten principles which were categorized into human rights, labor, environment and anti-corruption.

“It’s with the goal of achieving sustainability; companies need to adjust their corporate mindset from striving to be the best in the world to striving to be the best for the world, she said.

The United Nations Global Compact has inaugurated its two-year United Nations program to promote the ten principles and the SDGs of the United Nations Global Compact in Nigeria and contribute to the implementation of the broader United Nations development goals.

]]>
How safe are migraine medications for people with cardiovascular disease? https://mamaenlinea.com/2022/06/13/how-safe-are-migraine-medications-for-people-with-cardiovascular-disease/ Mon, 13 Jun 2022 21:49:20 +0000 https://mamaenlinea.com/2022/06/13/how-safe-are-migraine-medications-for-people-with-cardiovascular-disease/ Triptans were associated with fewer major adverse cardiovascular events (MACE) in patients with acute migraine with a history of cardiovascular disease compared to nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids/butalbital, according to registry data patients. Among those with acute migraine and at least one baseline cardiovascular disease, MACE occurred with 0.90% of triptan prescriptions, 4.52% of […]]]>

Triptans were associated with fewer major adverse cardiovascular events (MACE) in patients with acute migraine with a history of cardiovascular disease compared to nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids/butalbital, according to registry data patients.

Among those with acute migraine and at least one baseline cardiovascular disease, MACE occurred with 0.90% of triptan prescriptions, 4.52% of opioid/butalbital prescriptions, and 3.76% of NSAID prescriptions, Jessica Ailani, MD, of MedStar Georgetown University Hospital in Washington, DC, reported at the annual meeting of the American Headache Society.

The adjusted hazard ratios for MACE were 0.38 (95% CI 0.22-0.67, P=0.001) comparing triptans to opioids/butalbital and 0.46 (95% CI 0.29-0.71, P<0.001) comparing triptans to NSAIDs.

The prescribing information for triptans lists a history of cardiovascular disease as a contraindication, but it’s unclear whether triptans carry higher risks of cardiovascular events than other migraine treatments, Ailani noted.

“Triptans carry a black box warning to avoid their use in known cardiovascular diseases, Ailani said. MedPage today. “I believe that, even after the results of this summary, this disclaimer is still appropriate..

“Sometimes in practice, migraine patients with cardiovascular disease will be prescribed NSAIDs other than aspirin, opioids, or butalbital without being clear whether these treatments also pose risks,” Ailani pointed out.

“In clinical practice, we have scenarios where a patient has stable cardiovascular disease that is monitored over time, such as well-controlled hypertension or hyperlipidemia,” she added.

Analyzes have shown that more than one in five commercially insured migraine patients have cardiovascular disease that specifically contraindicates treatment with triptans. Another 25% had two or more cardiovascular risk factors identified as triptan warnings and precautions.

In their study, Ailani and colleagues identified adults treated for acute migraine with triptans, NSAIDs other than aspirin, and opioids/butalbital from January 2006 to December 2020 in the Mass General Brigham Research Patient Data Database. Registry. All participants had at least one diagnosis of baseline cardiovascular condition.

MACE was defined as nonfatal stroke, nonfatal MI, facility all-cause mortality, or a composite of the three outcomes. MACE was assessed from the index date until 60 days later, or the date of the change in treatment class, or the end of data availability, whichever comes first.

The index date was defined as the date of each eligible prescription. Multiple prescriptions per patient were included.

Only triptans prescribed as a single anti-migraine treatment were included in the analysis, and combination therapies of opioids/butalbital and NSAIDs other than aspirin were excluded.

The researchers identified 12,121 prescriptions for acute migraine: 4,016 for triptans, 6,084 for opioids/butalbital and 2,021 for NSAIDs. The most frequent index treatments were sumatriptan (Imitrex; 59%) in the triptans cohort, butalbital (38.5%) and oxycodone (27%) in the opioids/butalbital cohort and ibuprofen (61.5 %) in the NSAID cohort.

The mean index ages were 49, 54, and 47 years for the triptans, opioids/butalbital, and NSAIDs cohorts, respectively. Approximately 86% of patients in each group were female.

Compared to the triptan cohort, the opioid/butalbital and NSAID cohorts had higher baseline aspirin use. These cohorts also had a higher likelihood of baseline cardiovascular risk (2.4% for opioids/butalbital, 3.3% for NSAIDs, and 1.6% for triptans). Even after taking this into account, the risk of MACE was still higher for these patients, especially for those who prescribed opioids and butalbital, Ailani noted.

The analysis had several limitations, Ailani acknowledged. Prescription data does not provide information about medication dispensing, compliance, or compliance, which can lead to misclassification of exposure. Only prescription NSAIDs were evaluated, not over-the-counter use.

The study relied on diagnostic codes, which may also have led to misclassification, she added. Residual or unmeasured confusion may have influenced the conclusions, and patients at Mass General Brigham are different from patients in other parts of the country.

“My takeaway is that opioids and butalbital-containing products can pose more risks than just medication overuse headaches and we as prescribers have to be very careful in viewing them as a safe alternative in people at cardiovascular risk,” Ailani observed.

“This study, while having limitations, is a first step to questioning the safety of known treatments in migraine patients with cardiovascular disease,” she said.

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s disease, dementia, MS, rare diseases, epilepsy, autism, headaches , strokes, Parkinson’s disease, ALS, concussions, CTE, sleep, pain, etc. Follow

Disclosures

This analysis was supported by GlaxoSmithKline.

Ailani reported relationships with AbbVie, Amgen, Aeon, Axsome, Biohaven, BioDelivery Scientific International, Eli Lilly, GlaxoSmithKline, Lundbeck, Impel, Neurolief, Neso, Satsuma, Theranica, Teva, Zosano, and Ctrl M.

]]>
Side effects, use for migraine, dosage, etc. https://mamaenlinea.com/2022/05/22/side-effects-use-for-migraine-dosage-etc/ Sun, 22 May 2022 07:00:00 +0000 https://mamaenlinea.com/2022/05/22/side-effects-use-for-migraine-dosage-etc/ Before you start taking Zomig, talk to your doctor about your treatment plan. Be sure to discuss: your general health and medical history any other medical condition you have any other medicines you are taking These and other considerations are described below. interactions Taking medicine with certain vaccines, foods, and other things can affect how […]]]>

Before you start taking Zomig, talk to your doctor about your treatment plan. Be sure to discuss:

  • your general health and medical history
  • any other medical condition you have
  • any other medicines you are taking

These and other considerations are described below.

interactions

Taking medicine with certain vaccines, foods, and other things can affect how the medicine works. These effects are called interactions.

Before taking Zomig, be sure to tell your doctor about all medications you are taking, including prescription and over-the-counter medications. Also describe any vitamins, herbs or supplements you use. Your doctor or pharmacist can tell you about any interactions these may cause with Zomig.

Interactions with Medications or Supplements

Zomig may interact with several types of medications. These drugs include:

This list does not contain all types of drugs that may interact with Zomig. Your doctor or pharmacist can tell you more about these interactions and any other interactions that may occur with Zomig.

Warnings

Zomig may not be right for you if you have certain medical conditions or other factors that affect your health. Talk to your doctor about your medical history before taking Zomig. Factors to consider include those listed below.

Heart attack. Because of the heart attack risk associated with Zomig, doctors generally won’t prescribe the drug to people with certain heart conditions. This includes coronary artery disease. If you have risk factors for heart disease, your doctor will check your heart health before prescribing Zomig. Examples of risk factors include high blood pressure and diabetes.

Irregular heart rate or rhythm. Zomig may affect the way your heart beats. Because of this risk, doctors will not prescribe Zomig to people with certain heart conditions. Tell your doctor about any heart problems you have. They will discuss with you if Zomig is a safe treatment for your migraine episodes.

Stroke. In rare cases, triptans such as Zomig can cause strokes that can be fatal. Because of this risk, if you have had a stroke your doctor may not prescribe Zomig for you. They will discuss with you other treatment options that you can safely take.

Blood vessel problems. Zomig can cause blood vessel spasms. This can cause blood clots to form and block blood flow to certain parts of the body. If you have a history of blood vessel spasms, taking Zomig may increase your risk of blood flow and clotting problems. If you have blood vessel disease or a history of blood vessel problems, your doctor may recommend other, safer treatments.

Phenylketonuria. Phenylketonuria is a genetic condition that causes increased blood levels of a substance called phenylalanine. Zomig-ZMT orally disintegrating tablets contain phenylalanine, which may aggravate this condition. If you suffer from phenylketonuria, talk to your doctor before taking Zomig. They will probably prescribe Zomig tablets instead.

Hepatic insufficiency. In people with moderate to severe liver impairment, Zomig can build up to high levels in the blood. Higher blood levels of Zomig may increase the risk of side effects. If you have moderate to severe liver impairment, your doctor probably won’t prescribe Zomig nasal spray for you. Talk to your doctor about other treatments for your condition that can be taken safely.

High blood pressure. Zomig can cause an increase in blood pressure. In people with high blood pressure, the drug may make this condition worse. If you manage your high blood pressure with medication, you should monitor your blood pressure more often while taking Zomig. If you have uncontrolled high blood pressure, your doctor may not prescribe Zomig for you. They will discuss with you other safer treatments to relieve your migraine symptoms.

Allergic reaction. If you’ve had an allergic reaction to Zomig or any of its ingredients, your doctor probably won’t prescribe Zomig for you. Ask them what other medications are better options for you.

Zomig and alcohol

Although some drugs interact with alcohol, Zomig is not one of them.

But alcohol can trigger migraine episodes in some people. You may want to avoid alcohol or limit your intake.

Before starting Zomig, ask your doctor or pharmacist if it is safe to drink alcohol.

Pregnancy and breastfeeding

It is not known if Zomig is safe during pregnancy. If you are pregnant or planning to become pregnant, talk to your doctor before taking Zomig.

Experts suggest that untreated migraine episodes may increase the risk of pregnancy complications. If you are pregnant and suffer from migraine, talk to your doctor to find the safest treatment for you.

It is not known if Zomig passes into breast milk and what effects it may have on nursing infants.

If you are breastfeeding or plan to breastfeed, talk to your doctor about whether it is safe to do so while taking Zomig. Your doctor will help you decide if the benefits of taking Zomig outweigh any possible risks during this time.

]]>
Educated Patient® MPN Summit Diagnostics and Treatment Panel: May 7, 2022 https://mamaenlinea.com/2022/05/18/educated-patient-mpn-summit-diagnostics-and-treatment-panel-may-7-2022/ Wed, 18 May 2022 13:01:39 +0000 https://mamaenlinea.com/2022/05/18/educated-patient-mpn-summit-diagnostics-and-treatment-panel-may-7-2022/ This panel was moderated by Dr. Jamile Shammoand featured Dr. Aaron Gerds and Dr Bart Scott. Shamo: Scott, in the past, no treatment was recommended, since it only addressed the symptomatology of (myelofibrosis [MF]). So what does the research today show about early treatment and slowing the progression of myelofibrosis? Scott: Okay, so most of […]]]>

This panel was moderated by Dr. Jamile Shammoand featured Dr. Aaron Gerds and Dr Bart Scott.

Shamo: Scott, in the past, no treatment was recommended, since it only addressed the symptomatology of (myelofibrosis [MF]). So what does the research today show about early treatment and slowing the progression of myelofibrosis?

Scott: Okay, so most of this data would come from the use of interferon therapy. And there are smaller studies, which we call phase 2 trials, showing that using interferon can reverse myelofibrosis. It can also cause molecular remission, but we don’t yet know if this translates to improved survival. This is therefore an important point. And then if you look at the COMFORT trials, yes, there was an improvement in survival with treatment with (Jakafi [ruxolitinib]), but this treatment was given to patients with intermediate to high risk disease. And there is no evidence that early treatment of low-risk patients with myelofibrosis with ruxolitinib, federatinib or (Vonjo [pacritinib]), one of the “ibs”, no evidence that early treatment improves overall survival. There is evidence that if patients need treatment, they have more intermediate-risk or high-risk conditions that may improve survival if treated with ruxolitinib.

Shamo: Thank you. And the next question is in this regard. I don’t have a genetic mutation and I have MF, can it still turn into acute leukemia.

Gerds: Certainly yes. So these modern panels, these gene panels that we have, check 60, maybe even 100, or some 100 genes, okay. So each of your cells contains more than 60,000 genes. And so we check a very small part of the genome. And some of these tests look at specific points within a gene, they may not look at the whole gene and its entirety. So it’s reasonable to think that for a lot of patients with quotes, triple negative, or myelofibrosis where the mutation isn’t found, there is a mutation somewhere that could lead to disease progressing over time. It is unclear what it may be and what kind of risk it is associated with.

Shamo: Thank you. Next question, I guess either one could take this, but that’s fine. Can you talk about iron deficiency anemia, I am on Jakafi and had phlebotomy in three years. I assume this is a PV patient, I am now taking iron supplements with a lot of fatigue which is not like me. So what does iron deficiency do to someone who may be on Jakafi?

Scott: To the right. Thus, the development of fatigue is a complicated problem in the field of MPNs. And there are several reasons why this could happen. And one of them is iron deficiency. So I didn’t talk about it for lack of time. But when you put a patient on cytoreduction, one of the goals of that cytoreductive treatment is to make sure that patients no longer need to undergo phlebotomy. And if you are able to do this successfully you may want to consider replenishing iron because iron deficiency can lead to high platelet count which you didn’t already want someone with implants it can cause fatigue, it can cause restless leg syndrome, and it can cause food puffiness. So in an ideal world, if you no longer need to receive about, and you’re on the spot, a reducing treatment, it would be nice to top up the iron.

But patients may have continued fatigue, despite adequate iron replacement. So one of the things that could be done is to assess the iron levels in an individual like this and make sure they’ve had adequate iron restoration. And if this happened, there may be other reasons for fatigue. And one of the things that can happen in patients with polycythemia vera is that they can progress to myelofibrosis, for example. So persistent fatigue, despite iron replacement, but a sign of progression of myelofibrosis. So it’s just something to consider the differential.

Shamo: I agree with that. And I guess I know there was talk about the NMP symptom assessment score and how we approach that. And I guess the question is, how do you calculate the contribution of NMPs to symptoms in someone who may have other comorbidities? So we always tend to be blamed and while patients have other comorbidities. How are you doing that?

Gerds: Well, for a lot of patients who may be inseparable, you know they’re different diseases, because unless you completely remove that disease from their body, you’ll never really know. We can get clues, okay. So if we say, you know, for example, use a JAK inhibitor, which we would expect to improve certain symptoms. And we see those symptoms getting better after starting a JAK inhibitor, well, then we can attribute those symptoms, at least that proportion of the symptom to the disease.

Likewise, when you stop a treatment and the symptoms return, that would also indicate that this is the source of that symptom. And you know, you think about other diseases and their treatment. Again, if somebody has sleep apnea, and that’s contributing to fatigue, once they start CPAP, or they have one of these new sleep apneas, pacemaker-type stuff cardiac, and his sleep apnea improves, well, and then his fatigue improves, well, then it was probably sleep apnea, if they fix the sleep apnea, and their fatigue doesn’t get any better than it would suggest again, going back to saying, well, maybe it was their MPN that caused this symptom all along. So really, it’s a bit of trial and error, in some cases, but it’s really hard to separate them because they’re all inside of one person. And unless you can completely rule out the disease, whether there was a full contributor, it’s really hard to know.

Shamo: I totally agree. Then, is there a direct causality between et and chronic migraine with aura?

Gerds: Oh, boy, I’ll choose that one. Um, again, you know, it seems like there’s an increased risk or patients are more likely to have headaches, whether it’s ocular migraines or some kind of migraine classic, there’s definitely that association there. And, you know, it tends to be something where you have to attack from both angles. So you need specific migraine therapy, whether it’s avoiding the triggers, you know, drugs like Imitrex, and that can help relieve migraines, as you know, dealing with aliens. So in ET we’ll be using things like aspirin for those microvascular disturbances as well as reducing the number of tries to improve those symptoms. So again, yes, they’re related, they’re connected. And often, however, we have to deal both ways.

Shamo: I am okay. And I think that ties into your previous point that we have to it’s kind of a trial and error that if you deal with an entity and say somebody’s platelet count is optimized, and they continue to have a migraine, well, then you have to treat the migraine etc.

Next is for Dr. Scott, can we take a break from medication when we take hydroxyurea for PV, and can we take some time off medication to give our bodies a rest.

Scott: I generally don’t recommend it due to concerns about proliferation and the risk of thrombotic complications. Thrombosis is the leading cause of death for patients with polycythemia vera, and maintaining a hematocrit below 45, white count below 11,000, and platelet count below 600,000 is an important of this treatment. So I would say that if there are issues with the administration of hydroxyurea and the patient has symptoms, a better way to address that issue is to consider other types of therapeutic interventions. And Jakafi is FDA approved for patients whose second line treatment, if they fail, are hydroxyurea intolerant, and as I mentioned the proud PD trial showed a composite endpoint similar over 12 months with CHR and reduced spleen size comparing online pegylated interferon to hydroxyurea so people have problems with hydroxyurea a better way to approach what is considered as different therapeutic treatments, rather than stopping the treatment.

Shamo: I totally agree. So why don’t we have some final thoughts from Dr. Gerds and Dr. Scott, before we wrap up, and then maybe we can take a break after that? Let’s start with Dr. Gerds.

Gerds: Thank you. Thank you very much again, you know, thank you all for tuning in. And, you know, learning about your disease, you know, those things are incredibly complicated. And there are so many things that influence how an individual can feel and how their journey can unfold. So I think, you know, kind of the takeaway here, everyone’s background and background can be different. And really developing a relationship with your healthcare providers, your doctors, your nurses, and your nurse practitioners is really important. This way you get the best treatment possible based on what is going on with you at the time. So I know there are a lot of good discussions to come and new things to come. So I’m sure that the continuation of the talks will be very exciting.

Scott: Thank you. I would like to thank all the patients who have contributed to our understanding of this disease, and participation in a clinical trial is always an option for your care.

Raw transcripts have been lightly edited for clarity.

For more information on cancer updates, research and education, be sure to sign up for CURE® newsletters here.

]]>
Sumatriptan Succinate Market Size, Type, Application, Growth, Opportunity and Forecast to 2028. – ManufactureLink https://mamaenlinea.com/2022/05/02/sumatriptan-succinate-market-size-type-application-growth-opportunity-and-forecast-to-2028-manufacturelink/ Mon, 02 May 2022 11:42:26 +0000 https://mamaenlinea.com/2022/05/02/sumatriptan-succinate-market-size-type-application-growth-opportunity-and-forecast-to-2028-manufacturelink/ The sumatriptan succinate market is expected to grow at a CAGR of 8.46% by 2027. New York, USA: Research Sumatriptan Succinate Market report released by DECISIVE MARKET OVERVIEW deciphers a clear idea regarding modern market segmentation along with its segments and sub-segments. It is very necessary to have a comprehensive idea of ​​reading modern market […]]]>

The sumatriptan succinate market is expected to grow at a CAGR of 8.46% by 2027.

New York, USA: Research Sumatriptan Succinate Market report released by DECISIVE MARKET OVERVIEW deciphers a clear idea regarding modern market segmentation along with its segments and sub-segments. It is very necessary to have a comprehensive idea of ​​reading modern market segmentation to deeply understand the overall behavior of the market. An accurate representation of the most likely CAGR percentage over the forecast period of 2020-2027 has been carefully incorporated. All the crucial factors of global marketing are included in detail, such as gross margins, total sales and marketing volume, overall production and consumption quantity, import, export, competitive landscape analysis , in-depth pricing analysis, vendor landscapes, key investments. domains, advanced graphical representations, vital parameters for proper market valuation, asset management, modern market regulations, market size, etc. Various licensing strategies such as trademark licensing, copyright licensing, trade secret licensing, exclusive and non-exclusive licensing, etc. adopted by global market leaders to gain an added advantage from a competitive point of view.

For Sample Copy of Report Visit @ https://www.decisivemarketsinsights.com/sumatriptan-succinate-market/57851136/request-sample

Sumatriptan Succinate Market Segmentation-
By type:
Tablet Subcutaneous injection Nasal spray
Per application:
Oral subcutaneous injection
By key players: Dabur Pharmaceuticals Mylan Sandoz Roxane Pa Teva Imitrex GlaxoSmithKline Sun Pharmaceutical

This report is broad in concept and content directly from Sumatriptan Succinate market
The COVID-19 pandemic has significantly hampered the overall market growth. Despite this unfavorable situation prevailing in the global market, there is a great need to initiate bold measures and define a set of new strategies to maintain the sustainability of the growth of the global market.

Why Should You Buy This Sumatriptan Succinate Market Report?
• Outstanding presentations can be prepared for a client as well as effective and efficient recommendations can be delivered to the executive of a particular organization.
• Various promotional tactics, various time-saving marketing strategies, research methodologies and methods for modifying a business plan are well explained.
• A 360 degree view of different marketing angles has been instilled along with a deep level of understanding of the nature of modern market competitors and their mentality of selling key products is briefly explained.

In order to make a pre-order request, please click on the link below:-https://www.decisivemarketsinsights.com/sumatriptan-succinate-market/57851136/pre-order-enquiry

Value Stream Analysis is a highly effective and modernized technique implemented by global businesses to accurately determine the set of major activities that enhance the value of its end product and thoroughly analyze these activities to a significant level. price reduction. Asset management is one of the go-to indicators in the global market that delineates the variety of techniques for managing major assets using key financial instruments.

HEART AND SOUL OF THE Sumatriptan Succinate Market REPORT:-
• Report includes CAGR, BCG Matrix, Breakeven Analysis, PORTER 5 Forces and PESTEL Analysis.
• This report includes points that influence customer expectations for new products and services, sources of desired product and service expectations, sources of adequate product and service expectations, sources of products and services desired and planned, the decision made by a senior executive if customer expectations are “unrealistic.
• Strategic brand and product management is also highlighted in the report.
• Different public relations activities of world leaders during the crisis are also mentioned in the report.

To inquire about the discount, please fill out the form by clicking the link below:-https://www.decisivemarketsinsights.com/sumatriptan-succinate-market/57851136/request-discount

Key Questions Answered by Decisive Markets Insights in the Sumatriptan Succinate Market Report:-
(1) What are the various opportunities that the global market leaders can count on to generate more profit during the forecast period 2020-2027?
(2) What are the different challenges that a company may face in the long term and what are the opinions of industry experts to overcome these challenges?
(3) What will be the condition of the global market in the next 6-7 years with its CAGR?
(4) Who are all our major competitors and what are the different business strategies they adopt to stay ahead of the competition?

Please click on the link below if you intend to make a direct purchase @:-https://www.decisivemarketsinsights.com/sumatriptan-succinate-market/57851136/buy-now

Key Questions Answered by Decisive Markets Insights in the Sumatriptan Succinate Report:-
(1) What will be the impact of rigid government policies on the global Sumatriptan Succinate market during the forecast period 2020-2027?
(2) What are the key strategies adopted by global Sumatriptan Succinate market leaders to enhance their business growth?
(3) What are the various methods to effectively analyze the overall Sumatriptan Succinate Market growth?
(4) What will be the scenario of the global market during the forecast period 2020-2027 with its CAGR?

Please contact us and our expert will get back to you within 30 minutes:

Critical market insights
Sunil Kumar
Head of sales
WE :+18317045538
UK :+441256636046
E-mail – [email protected]
Address – 26 Broadway, Suite 934, New York – 10004.

Website – https://www.decisivemarketsinsights.com/
Social connections :
Twitter:- https://twitter.com/decisivemarket
Linkedin:- https://www.linkedin.com/company/decisive-markets-insights

]]>
Barriers to Axsome AXS-07 migraine treatment beyond FDA approval, its https://mamaenlinea.com/2022/04/29/barriers-to-axsome-axs-07-migraine-treatment-beyond-fda-approval-its/ Fri, 29 Apr 2022 15:45:15 +0000 https://mamaenlinea.com/2022/04/29/barriers-to-axsome-axs-07-migraine-treatment-beyond-fda-approval-its/ Central nervous system (CNS) specialist Axsome Therapeutics (Nasdaq: AXSM) expects to receive a full response letter (CRL) from the FDA due to chemistry, manufacturing and control (CMS) issues recently revealed during of the FDA’s review of its New Drug Application for AXS-07 (rizatriptan and meloxicam), for the acute treatment of migraine headaches. According to the […]]]>

Central nervous system (CNS) specialist Axsome Therapeutics (Nasdaq: AXSM) expects to receive a full response letter (CRL) from the FDA due to chemistry, manufacturing and control (CMS) issues recently revealed during of the FDA’s review of its New Drug Application for AXS-07 (rizatriptan and meloxicam), for the acute treatment of migraine headaches.

According to the report by industry analyst firm GlobalData, “Migraine Drug…

This article is accessible to registered users, to continue reading, please register for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space for one week. If you are already a registered user, please login. If your trial period is over, you can register here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science journalists.
• Receive The Pharma Letter daily newsletter, free forever.

Become a subscriber

• Unfettered access to top pharmaceutical and biotechnology industry news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patent and legal, executive appointments, business strategy and financial results.
• Daily roundup of key events in pharma and biotechnology.
• In-depth monthly briefings on board appointments and M&A news.
• Choose between an economical annual plan or a flexible monthly subscription.

]]>
New Migraine Treatments Offer More Options to Relieve and Prevent Symptoms https://mamaenlinea.com/2022/04/28/new-migraine-treatments-offer-more-options-to-relieve-and-prevent-symptoms/ Thu, 28 Apr 2022 15:00:15 +0000 https://mamaenlinea.com/2022/04/28/new-migraine-treatments-offer-more-options-to-relieve-and-prevent-symptoms/ Migraines affect just over 10% of the world’s population and are still poorly understood. Fortunately, recent advances in treatment have given doctors and patients more tools in their toolbox to prevent or relieve migraine symptoms. A migraine is defined as a recurring throbbing headache that usually affects one side of the head, resulting in moderate […]]]>

Migraines affect just over 10% of the world’s population and are still poorly understood. Fortunately, recent advances in treatment have given doctors and patients more tools in their toolbox to prevent or relieve migraine symptoms.

A migraine is defined as a recurring throbbing headache that usually affects one side of the head, resulting in moderate to severe pain. It is often accompanied by additional symptoms such as nausea, fatigue, and sensitivity to light and sound.

Although the definitive cause of the condition is not fully understood, it is postulated that migraines are caused by changes in trigeminal nerve and neurotransmitter imbalances. As neurotransmitters, such as serotonin, decrease, the body releases neuropeptides, which signal cranial blood vessels to expand and let in more blood.

Migraines can be triggered by different things in different people. Various triggers have been observed, including certain foods, alcohol, and sensory stimuli such as loud sounds and glare from the sun. The first non-drug step in treating migraines is to identify personal triggers and try to avoid them as best you can. Many patients start by creating a headache journal or diary to help identify triggers and patterns.

Before visiting some of the new migraine treatments, it pays to review previously established treatment regimens. Generally, the treatment of migraine can be categorized into 2 main segments: acute drug treatment and prophylactic drug treatment.

To treat acute symptoms, many undiagnosed patients with migraines begin by taking over-the-counter pain relievers such as acetaminophen (Tylenol; Johnson & Johnson), ibuprofen (Motrin; McNeil Consumer Healthcare), naproxen ( Aleve; Bayer) or a combo containing aspirin, acetaminophen and caffeine (Excedrin). These options will generally alleviate the symptoms of a milder to moderate form of migraine, but more moderate to severe forms will tend to require prescription medication.

The most common prescription options for acute treatment include serotonin receptor agonists (triptans), ergotamine medications, and butalbital-containing medications.

Triptans are selective 5-HT1 receptor agonists. They work by constricting blood vessels in the brain, which inhibits the release of neuropeptides and decreases the transmission of pain. Triptans are still considered first-line in the treatment of migraines. Some examples of triptans include sumatriptan (Imitrex; GSK), rizatriptan (Maxalt; Merck), zolmitriptan (Zomig; AstraZeneca), and eletriptan (Relpax; Pfizer).

Triptans are primarily manufactured as immediate-release tablets, which allow for a fairly rapid onset of action. There are, however, a few special formulations that allow for an even faster onset, such as sumatriptan, rizatriptan and zolmitriptan orally disintegrating tablets, zolmitriptan nasal spray, and sumatriptan subcutaneous injections.

Products containing ergotamine are non-selective serotonin receptor agonists and are considered second-line. These are usually reserved for patients who find no relief from triptans. Ergotamine and caffeine (Cafergot; Altura Pharmaceuticals) are available as tablets and suppositories (Migergot; Cosette Pharmaceuticals). Dihydroergotamine comes as an injection (DHE 45; Valeant) and a nasal spray (Migranal; Valeant).

Products containing butalbital, opioids and other controlled pain relievers, although sometimes prescribed, are not recommended for the treatment of migraine due to their abuse/dependence potential. They are often used in cases where no other treatment seems to be beneficial. Examples of products containing butalbital include acetaminophen/butalbital/caffeine (Fioricet; Actavis) and aspirin/butalbital/caffeine (Fiorinal; Allergan). Both of these combinations also have a version with codeine as an additional ingredient.

In terms of prophylactic treatment, the objective is to reduce the frequency of migraine attacks. Patients are eligible for prophylactic treatment when they must use acute treatments for 2 or more days in 1 week or 3 or more times per month. Beta-blockers, such as propranolol (Inderal; AstraZeneca) and metoprolol (Lopressor; Novartis), and antiepileptics, such as divalproex (Depakote; Abbvie) and topiramate (Topamax; Janssen), are often used daily to prevent migraine attacks.

Botulinum toxin type A (Botox; Allergan) is used for chronic migraine prophylaxis. It is injected into the nerves around the pain fibers involved in headaches. It then blocks the release of chemicals and prevents the pain activation chain. A treatment will last approximately 10 to 12 weeks.

A relatively new class used in migraine prevention is the calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is a protein implicated in the cause of migraine, and by modulating the levels in the body, prevention is achieved. There are 2 types of CGRP inhibitors: monoclonal antibodies and gepants.

The group of monoclonal antibodies targets either CGRP directly or the receptor to which CGRP binds. Erenumab (Aimovig; Amgen/Novartis), fremanezumab (Ajovy; Teva), and galcanezumab (Emgality; Eli Lilly) are all subcutaneous injections typically used once a month. Eptinezumab (Vyepti; Lundbeck) is a new intravenous version approved in 2020 that is given every 3 months.

Gepants is an unofficial name for a new type of oral formulation of CGRP receptor antagonists, which includes ubrogepant (Ubrelvy; Allergan), rimegepant (Nurtec ODT; Biohaven) and atogepant (Qulipta; Abbvie) . These drugs block the CGRP receptor and are effective in both relieving migraines and preventing them.

One of the newer drugs marketed for the treatment of migraine is lasmiditan (Reyvow; Eli Lilly), which is the first and only type of its class of 5-HT1F serotonin agonists. It acts on specific receptors present on the nerves responsible for transmitting pain rather than on the blood vessels. This means that it produces migraine relief without having a constricting effect on blood vessels, which makes it more suitable for use in patients who also suffer from vascular disease.

Dihydroergotamine was previously listed in the class of ergotamines; however, the FDA recently approved a new nasal spray formulation (Trudhesa; Impel Neuropharma) that uses a new, proprietary delivery system that allows the drug to penetrate deeper into the nasal cavity, increasing absorption.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a common class of painkillers used to relieve migraine pain. Over-the-counter versions such as naproxen and ibuprofen have been mentioned previously. There is a new liquid prescription NSAID, celecoxib (Elyxyb; Dr. Reddy’s), which is pending approval.

Finally, neuromodulation devices are becoming increasingly popular as a preventative treatment. A device that manipulates electrical currents and/or magnets is used to alter brain activity. There are currently four devices that have been approved by the FDA and are considered to have minimal risk or little or no adverse effects.

As essential partners in achieving the best health outcomes for patients, it’s important for pharmacists to stay abreast of advances in migraine treatments that have the potential to improve the health and quality of life of millions of people.

About the Author

Steven P. Mathew, PharmDis a senior pharmacist at Community Care Rx, which is a full-service long-term care pharmacy with offices in Hempstead, New York and Totowa, New Jersey.

]]>